Skip to search formSkip to main contentSkip to account menu

Busulfan/Melphalan Regimen

Known as: BuMel, BuMel Regimen, Busulfan-Melphalan Regimen 
A chemotherapeutic regimen composed of busulfan and melphalan used as a conditioning regimen for stem cell transplantation (SCT).
National Institutes of Health

Related topics

Related topics

2 relations
BusulfanMelphalan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the…
Hematopoietic stem cell transplantation (HSCT) is currently the standard of care for many malignant and nonmalignant blood… 
Highly Cited
2018
Highly Cited
2018
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.
Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A… 
2018
2018
Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience
High-risk neuroblastoma is characterized by poor long-term survival, especially for very high-risk (VHR) patients (poor response… 
Review
2018
Review
2018
Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
Background High-dose melphalan (HDMEL) represents the standard conditioning regimen before autologous stem cell transplant (ASCT… 
2016
2016
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases…
11001Background: EE99R2pul (ISRCTN61438620) was conducted in 16 countries, by 5 cooperative groups: COG, SFCE/GSF, GPOH, UK CCLG… 
2016
2016
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).
11000Background: EE99R2Loc (ISRCTN61438620) was conducted in 12 countries, by 4 cooperative groups: GPOH, SFCE/GSF, UK-CCLG, and… 
2013
2013
131I‐MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma
131I‐metaiodobenzylguanidine (MIBG) produces a 37% response rate in relapsed/refractory neuroblastoma, and could be used to… 
2013
2013
Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT
Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT 
2011
2011
Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.
2 Background: The HR-NBL1 trial of the European SIOP Neuroblastoma Group randomised 2 MAT regimens with the primary aim to… 
2010
2010
Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell…
Abstract 690 Background: BEAM is considered standard HDC for primary refractory or relapsed HL. However, pts with refractory HL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)